Three Sensei directors to resign, new CEO & CFO conditional on stockholder approval

Sensei Biotherapeutics, Inc.

Christopher Gerry, Thomas Ricks, Kristian Humer resigning conditionally effective after June 10, 2026 annual meeting, contingent on stockholder approval of Conversion and Charter Amendment Proposals.
Conditional appointments of Stephen Hahn, Saira Ramasastry, Karen Vousden as new directors effective at same time.
If proposals approved, Anand Parikh (current COO) will become CEO; Brian Stephenson will become CFO. Gerry remains General Counsel, Craver remains SVP Finance.
Board adopted Severance and Change in Control Plan covering Parikh, Gerry, Craver with cash severance up to 18 months base salary and COBRA.
Conversion Proposal involves issuance of >20% of common upon Series B preferred conversion, resulting in change of control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.